桑色素作为MMP-9抑制剂通过下调Notch-1信号减轻动脉粥样硬化中的内皮-间质转化
本研究探讨桑色素是否通过抑制内皮-间质转化(EndMT)缓解动脉粥样硬化及其机制。体外用TGF-β1诱导HUVECs的EndMT模型,体内用高脂饮食喂养ApoE-/-小鼠动脉粥样硬化模型。桑色素呈剂量依赖性抑制EndMT标志物,50 μmol/L抑制MMP-9和Notch-1信号上调,50 mg/kg口服4周减轻主动脉内膜增生和斑块形成,且与MMP-9有强结合亲和力。结论:桑色素作为MMP-9抑制剂通过限制Notch-1信号激活阻断EndMT。
要点
- 桑色素呈剂量依赖性抑制TGF-β1诱导的HUVECs EndMT标志物表达。
- 50 μmol/L桑色素抑制MMP-9和Notch-1信号上调,MMP-9过表达可逆转其抑制作用。
- 50 mg/kg桑色素口服4周减轻HFD诱导的ApoE-/-小鼠主动脉内膜增生和斑块形成。
核心结论
- 桑色素作为MMP-9抑制剂,通过限制Notch-1信号激活阻断动脉粥样硬化中的内皮-间质转化。
- 本研究提示桑色素在抗动脉粥样硬化药物开发中具有潜在应用价值。
研究设计与样本
- 体外实验:用10 ng/mL TGF-β1刺激人脐静脉内皮细胞(HUVECs)48 h诱导EndMT模型。
- 体内实验:使用高脂饮食喂养的载脂蛋白E(ApoE)-/-小鼠动脉粥样硬化模型,干预组口服桑色素50 mg/kg 4周。
- 采用分子对接和微量热泳动技术检测桑色素与MMP-9的相互作用。
主要发现
- 桑色素在TGF-β1处理的HUVECs中呈剂量依赖性抑制EndMT标志物表达。
- 50 μmol/L桑色素抑制TGF-β1诱导的EndMT中MMP-9和Notch-1信号的上调。
- MMP-9过表达激活Notch-1信号,逆转桑色素对EndMT的抑制作用。
- 在HFD诱导的ApoE-/-小鼠中,桑色素通过抑制EndMT显著减少主动脉内膜增生和斑块形成。
- 桑色素与MMP-9表现出强结合亲和力。
临床怎么用
- 桑色素可能作为MMP-9抑制剂用于抗动脉粥样硬化,但需进一步临床研究验证。
- 本研究为中药单体成分干预动脉粥样硬化提供了实验依据,提示靶向MMP-9/Notch-1轴可能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Atherosclerotic cardiovascular disease poses a significant health challenge globally. Recent findings highlight the pivotal role of the endothelial-to-mesenchymal transition (EndMT) in atherosclerosis. Morin is a bioflavonoid mainly extracted from white mulberry, a traditional Chinese herbal medicine with anti-inflammatory and antioxidant properties. This study examines whether morin can alleviate atherosclerosis by suppressing EndMT and seeks to elucidate the underlying mechanism. METHODS: We induced an in vitro EndMT model in human umbilical vein endothelial cells (HUVECs) by stimulating the cells with transforming growth factor-β1 (TGF-β1) (10 ng/mL) for 48 h. The in vivo experiments were performed in an atherosclerosis model using apolipoprotein E (ApoE)-/- mice fed with a high-fat diet (HFD). Mice in the intervention group were given morin (50 mg/kg) orally for 4 weeks. Molecular docking and microscale thermophoresis were assayed to understand the interactions between morin and matrix metalloproteinase-9 (MMP-9). RESULTS: Morin inhibited the expression of EndMT markers in a dose-dependent manner in TGF-β1-treated HUVECs. Administering 50 μmol/L morin suppressed the upregulation of MMP-9 and Notch-1 signaling in TGF-β1-induced EndMT. Moreover, the overexpression of MMP-9 activated Notch-1 signaling, thereby reversing morin's inhibitory effect on EndMT. In the HFD-induced atherosclerotic ApoE-/- mice, morin notably reduced aortic intimal hyperplasia and plaque formation by suppressing EndMT. Furthermore, morin demonstrated a strong binding affinity for MMP-9. CONCLUSION: Morin acts as an MMP-9 inhibitor to disrupt EndMT in atherosclerosis by limiting the activation of Notch-1 signaling. This study underscores morin's potential utility in the development of anti-atherosclerotic medication. Please cite this article as: He Y, Qin XX, Liu MW, Sun W. Morin, a matrix metalloproteinase 9 inhibitor, attenuates endothelial-to-mesenchymal transition in atherosclerosis by downregulating Notch-1 Signaling. J Integr Med. 2024; 22(6): 684-696.
引用
- He Y, Qin XX, Liu MW, et al. Morin, a matrix metalloproteinase 9 inhibitor, attenuates endothelial-to-mesenchymal transition in atherosclerosis by downregulating Notch-1 signaling. J Integr Med. 2024. PMID: 39572351. doi:10.1016/j.joim.2024.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。